BlackRock’s Applied Therapeutics APLT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,251,462
| Closed | -$325K | – | 5687 |
|
|
2025
Q4 | $325K | Sell |
3,251,462
-592,271
| -15% | -$376K | ﹤0.01% | 4600 |
|
|
2025
Q3 | $2.33M | Sell |
3,843,733
-1,375,953
| -26% | -$648K | ﹤0.01% | 4048 |
|
|
2025
Q2 | $1.62M | Sell |
5,219,686
-4,331,616
| -45% | -$1.68M | ﹤0.01% | 4131 |
|
|
2025
Q1 | $4.67M | Buy |
9,551,302
+255,227
| +3% | +$150K | ﹤0.01% | 3671 |
|
|
2024
Q4 | $7.96M | Buy |
9,296,075
+2,353,376
| +34% | +$14.8M | ﹤0.01% | 3540 |
|
|
2024
Q3 | $59M | Buy |
6,942,699
+372,912
| +6% | +$2.2M | ﹤0.01% | 2372 |
|
|
2024
Q2 | $30.7M | Buy |
6,569,787
+5,580,510
| +564% | +$26.4M | ﹤0.01% | 2722 |
|
|
2024
Q1 | $6.73M | Buy |
989,277
+461,391
| +87% | +$2.07M | ﹤0.01% | 3552 |
|
|
2023
Q4 | $1.77M | Buy |
527,886
+143,893
| +37% | +$358K | ﹤0.01% | 4085 |
|
|
2023
Q3 | $956K | Sell |
383,993
-14,033
| -4% | -$23.1K | ﹤0.01% | 4258 |
|
|
2023
Q2 | $509K | Buy |
398,026
+125,015
| +46% | +$166K | ﹤0.01% | 4479 |
|
|
2023
Q1 | $221K | Sell |
273,011
-20,770
| -7% | -$20.5K | ﹤0.01% | 4744 |
|
|
2022
Q4 | $223K | Sell |
293,781
-234,265
| -44% | -$185K | ﹤0.01% | 4822 |
|
|
2022
Q3 | $490K | Buy |
528,046
+39,108
| +8% | +$46.9K | ﹤0.01% | 4735 |
|
|
2022
Q2 | $463K | Sell |
488,938
-874,465
| -64% | -$1.43M | ﹤0.01% | 4796 |
|
|
2022
Q1 | $2.88M | Buy |
1,363,403
+64,872
| +5% | +$174K | ﹤0.01% | 4234 |
|
|
2021
Q4 | $11.6M | Buy |
1,298,531
+5,714
| +0.4% | +$75K | ﹤0.01% | 3590 |
|
|
2021
Q3 | $21.5M | Sell |
1,292,817
-19,285
| -1% | -$333K | ﹤0.01% | 3232 |
|
|
2021
Q2 | $27.3M | Buy |
1,312,102
+108,372
| +9% | +$2.05M | ﹤0.01% | 3111 |
|
|
2021
Q1 | $22.6M | Buy |
1,203,730
+147,570
| +14% | +$3.18M | ﹤0.01% | 3119 |
|
|
2020
Q4 | $23.2M | Buy |
1,056,160
+228,221
| +28% | +$4.75M | ﹤0.01% | 2923 |
|
|
2020
Q3 | $17.2M | Sell |
827,939
-3,143
| -0.4% | -$81.7K | ﹤0.01% | 2945 |
|
|
2020
Q2 | $30M | Buy |
831,082
+299,727
| +56% | +$12.5M | ﹤0.01% | 2578 |
|
|
2020
Q1 | $17.4M | Buy |
531,355
+245,750
| +86% | +$9.94M | ﹤0.01% | 2686 |
|
|
2019
Q4 | $7.79M | Buy |
285,605
+264,043
| +1,225% | +$4.52M | ﹤0.01% | 3363 |
|
|
2019
Q3 | $237K | Sell |
21,562
-6,142
| -22% | -$57.9K | ﹤0.01% | 4305 |
|
|
2019
Q2 | $228K | Buy |
+27,704
| New | +$262K | ﹤0.01% | 4338 |
|
BlackRock's APLT Position: Q1 2026 in Review
BlackRock sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 3,251,462 shares — an estimated $325K sold.
BlackRock first reported a position in APLT in Q2 2019 and held it in 27 quarters. The position peaked at $59M in Q3 2024. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.
- BlackRock reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 3,251,462 Applied Therapeutics shares in Q1 2026, an estimated $325K.
- BlackRock first reported a position in Applied Therapeutics in Q2 2019 and held it in 27 quarters.
- BlackRock's Applied Therapeutics position peaked at $59M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.